Scholar Rock Holding Corporatio (SRRK) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.81

Estimate

-$0.84

Surprise

+4.0%

Revenue (period 2026-09-30)

$570,000

Score today

5.3/10

Revenue source: xbrl.

Scholar Rock Holding Corporatio (SRRK) reported a narrower loss than forecast — adjusted EPS of -$0.81 against the -$0.84 estimate (a 4.0% beat on a still-unprofitable quarter).

• Scholar Rock Holding Q3 2026 Earnings Call Transcript — benzinga, 2026-11-10
• Scholar Rock Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-10
• BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In Cash — benzinga, 2026-11-10

TrendMatrix currently rates SRRK Sell at 5.3/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +4.0% surprise compares with a -0.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$48.00

Price target

$63.39

Stop

$44.64

Upside to target

+32.1%

Reward-to-risk

2.1:1

Model outputs from TrendMatrix’s engine as of 2026-11-11 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$5.85B

P/E (fwd)

-19.7

52-week range

$28.97–$61.76

Off 52-week high

22.3%

RSI (14)

63

Volume vs avg

1.20×

Score today

5.3/10